We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026
20 Aug 2026 - 22 Aug 2026

Oxycodone That Can't Be Abused or Misused

By HospiMedica staff writers
Posted on 22 Sep 2004
A new long-acting version of oral oxycodone incorporates features that prevent recreational use, prescription abuse, or accidental misuse.

Called Remoxy, the pain medication is now in clinical trials designed to confirm anti-abuse studies and pharmacokinetic studies. More...
Abusers can easily extract the full dose of oxycodone from currently marketed time-release preparations, which provides abusers with a fast and powerful morphine-like high. In 2002, oxycodone abuse resulted in more than 20,000 visits to emergency rooms and hundreds of deaths.

The new drug was developed by Pain Therpeutics, Inc. (South San Francisco, CA, USA). Remoxy incorporates deterrent properties and offers the convenience of twice-a-day dosing. Tests indicate that crushing or physically manipulating Remoxy does not defeat its time-release mechanism. The drug can also resist extraction by acids or alcohol for hours at a time by entrapping a majority of the oxycodone inside its proprietary formulation. Under a license agreement, Remoxy is formulated with the Saber technology of Durect Corp. (Cupertino, CA, USA). Saber is a patented technology based on sucrose acetate isobutyrate, a high-viscosity biodegradable liquid matrix that forms the basis for a number of different drugs.

"As oxycodone abuse has no national barriers, we continue to envision Remoxy as a safe, effective and reliable alternative to time-release oxycodone both in the U.S. and abroad,” noted Remi Barbier, president and CEO of Pain Therapeutics.




Related Links:
Pain Therapeutics

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.